BioLife Solutions, Inc. (BLFS): Q1 2026 Revenue Climbs 25% to $27.5M as EBITDA Hits $6.2M

Key numbers at a glance

BioLife Solutions, Inc., Nasdaq: BLFS, reported first-quarter 2026 revenue of $27.5 million, up 25% year over year. GAAP gross margin and non-GAAP adjusted gross margin both stood at 64%, underscoring a margin profile that the company has managed to preserve alongside top-line growth. GAAP net income totaled $1.2 million for the quarter, while non-GAAP adjusted EBITDA reached $6.2 million, or about 22% of revenue.

Despite the absence of a disclosed EPS figure in the release, the juxtaposition of a positive GAAP net income with a double-digit EBITDA margin paints a picture of a business delivering profitable scale, even as it continues to navigate the transition away from legacy divisions.

Management framed the results as a solid start to 2026, with a clear emphasis on ongoing demand for biopreservation media and a broader product portfolio driving recurring revenue—the kind of headline that investors look for when weighing an early 2020s CGT toolbox supplier against the backdrop of a still-fragile funding climate.

What the quarter reveals about BioLife’s business model

The company highlighted two structural strengths: a robust installed base of products with broad clinical traction and a disciplined approach to profitability as volume grows. BioLife notes that its biopreservation media is used in roughly 250 ongoing commercially sponsored clinical trials in the U.S., accounting for more than 70% of the market and including over 30 Phase III trials. Its CellSeal vials and hPL products are active in more than 35 clinical trials. This is a posture of scale in a sector where late-stage trials can be a proxy for long-term revenue visibility.

As for the mix, BioLife claims substantial embeddedness in 17 unique commercial CGTs as of March 31, 2026, with expectations of approvals for 9 additional products over the next year. That forward cadence—new approvals paired with existing trials—could translate into a more durable revenue stream if success compounds across indications and geographies.

Strategic context: evo divestiture and ongoing narrative

One notable strategic move from 2025 is the divestiture of evo, with BioLife presenting its current results from continuing operations and noting that prior periods are shown in discontinued operations for comparability. The impact is twofold: it clarifies the company’s focus on its core biopreservation and CGT-support products, and it streamlines cost and capital allocation toward higher-return growth drivers.

From a capital-structure perspective, the company’s emphasis on non-GAAP EBITDA provides a lens on operating profitability independent of one-time or structural adjustments tied to the evo sale. For readers who care about earnings per share (EPS) and EPS consensus, the release does not provide an EPS figure or forward EPS guidance, which means the market’s EPS surprise calculation will have to wait for supplemental disclosures or the next quarterly print.

Outlook, guidance, and what to watch

BioLife CEO commentary centers on optimism for 2026, anchored by continued demand in biopreservation media and CGT expansion. The company states that its results support a favorable full-year outlook, but it elects not to publish a precise revenue forecast in this release. That omission means investors won’t have a numeric EPS consensus target or a formal revenue forecast to anchor expectations around beats or misses in the near term.

Key levers to monitor include: continued growth in the CGT-installed base, progress toward approvals of the nine anticipated products, and the sustainability of gross margins as the company scales. In addition, the broader funding landscape for bioprocessing and cell therapy—an environment Mark-to-market investors watch closely—will influence the risk-reward calculus for BLFS peers and potential acquirers or strategic partners.

Implications for peers and the sector

The Q1 numbers reinforce a narrative in which suppliers of core CGT infrastructure—cell processing tools, media, and related consumables—benefit from a maturing pipeline that translates trial activity into recurring revenue streams. For BioLife’s close peers, the key takeaway is twofold: maintain margin discipline while scaling with trial momentum, and stay alert to any capacity or supply chain constraints that could affect the ability to meet surging demand across late-stage trials.

In a sector where earnings surprise and EPS consensus chatter often dominates the day, the absence of explicit forward EPS targets or a revenue forecast in BioLife’s release shifts the narrative toward execution and portfolio concentration. If BioLife can convert its 250-trial ecosystem and 17 CGTs into sustained top-line growth with a consistent EBITDA margin, its model could pressure peers to demonstrate comparable gross-margin resilience amid CGT expansion, regulatory variability, and continuing M&A activity in the space.

Bottom line for investors

BLFS offers a relatively clean narrative: revenue growth, stable margins, and profitability on an ongoing basis, backed by a high-volume trial footprint and selective divestiture that sharpens strategic focus. The absence of a published EPS figure or revenue forecast means the stock’s near-term trajectory may hinge more on execution signals—trial progress, product approvals, and margin progression—than on headline earnings surprises.

For those watching the sector, BioLife’s Q1 serves as a case study in balancing growth with profitability in a CGT-enabled ecosystem. The story isn’t about a single quarter’s performance so much as the ability to translate clinical momentum into durable cash flow—and to do so while keeping the door open to value-creating partnerships or bolt-on deals that could accelerate the next wave of growth.